Wall Street used to be the only game in town for American drug developers. If you were a San Diego biotech with promising clinical data, the script was already written for you. You raised a Series A, closed a Series B, and filed for a Nasdaq IPO as soon as humanly possible.
That playbook is breaking down.
Axiom Biosciences, a San Diego-based regenerative medicine firm, is flipping the traditional listing route on its head. Instead of knocking on doors in New York, Axiom is preparing a primary public listing on the Hong Kong Stock Exchange (HKEX). It plans to target $150 million to $200 million in fresh capital before pursuing a secondary U.S. listing years down the road.
This isn't an offshore tax trick. It's a calculated response to a structural squeeze in U.S. venture markets.
The Wall Street Funding Crunch Facing Mid-Tier Biotechs
The U.S. public biotech market has quietly split into two distinct worlds.
Mega-cap pharmaceutical giants and high-flying commercial-stage companies are swimming in cash. Everyone else is fighting for table scraps. If you're a early-to-mid stage biotech without a massive commercial partner, raising private capital in the U.S. over the last four years has been brutal.
Axiom ran lean. Operating with just 13 employees at its peak, the company raised roughly $14 million in equity alongside eight non-dilutive federal and state grants. It reached Phase 1 clinical milestones on a fraction of the budget that typical Wall Street darlings burn in a single quarter.
When it came time to scale up clinical trials for larger indications, the reality of Wall Street became obvious. Small-cap biotechs listing on Nasdaq frequently face predatory short selling, low trading liquidity, and punishing valuation discounts.
Asian markets offered a stark contrast. Hong Kong has spent the last few years quietly building an institutional investor base that actively craves early-stage life sciences risk.
Inside Axiom Biosciences and Its Play for Hong Kong
To understand why Hong Kong investors are interested, you have to look at what Axiom actually makes.
Formerly known as Cytonus Therapeutics, the company recently rebranded to Axiom Biosciences after posting remarkable early clinical data. Its lead therapeutic candidate targets two devastating condition in newborns: intraventricular hemorrhage (bleeding inside the brain's ventricles) and hypoxic-ischemic encephalopathy (brain damage caused by oxygen deprivation).
These conditions carry a historical first-year mortality rate near 46%. In Axiom's Phase 1 study of nine infants treated with its umbilical cord-derived mesenchymal stem cell therapy, the two-year mortality rate was zero.
The clinical data was developed in partnership with South Korea-based Medinno Inc.. The therapy has already secured two Rare Pediatric Disease Designations from the U.S. FDA. Axiom is also preparing to expand its technology platform into adult ischemic stroke, a massive market affecting roughly 700,000 Americans every year.
Even with strong science and FDA backing, chief executive officer Dr. Remo Moomiaie-Qajar knew that taking a niche stem cell company to Nasdaq in the current macro environment meant taking a massive hair-cut on valuation.
Axiom's cap table was already heavily tied to Asia. Seoul-based Partners Investment led its $11.7 million Series A back in 2023. Its clinical development partner was in South Korea. Going where the company's existing network lived made logical sense.
How Hong Kong's Chapter 18A Rules Opened the Door
Hong Kong didn't attract Axiom by accident. The city spent years revamping its financial regulations specifically to steal life science listings from New York and London.
The biggest catalyst was HKEX Chapter 18A.
Historically, Asian stock exchanges required long histories of profitability before a company could list. Chapter 18A threw those requirements out the window for biotech issuers. Under these specialized rules, pre-revenue and pre-profit clinical companies can go public if they meet clear regulatory checkpoints:
- A minimum market capitalization at the time of listing (typically HK$1.5 billion, or roughly $190 million).
- At least one core product that has completed Phase 1 clinical testing and received clearance from a major regulator to move into Phase 2.
- At least 12 months of operating capital covered.
- Meaningful third-party investment from sophisticated healthcare investors.
Because Axiom had already cleared its Phase 1 trials and proven safety in human neonates, it checked every single Chapter 18A box.
While Wall Street generalists often treat clinical-stage cell therapy as high-risk speculation, Hong Kong retail and institutional investors view Chapter 18A biotechs as growth engine assets. Recent biotech debuts on the HKEX have held their valuations significantly better than their U.S. peers.
Why Asian Capital Is Chasing Cell and Gene Therapy
There is a geographical alignment happening here that goes far beyond stock market mechanics.
East Asia has become a global epicenter for clinical research in regenerative medicine and advanced biologics. Hospitals across China, South Korea, and Japan conduct clinical trials at speed, with lower patient recruitment costs and streamlined clinical site coordination.
For a U.S. company developing cellular therapies, having a primary listing in Hong Kong creates direct bridges to Asian pharmaceutical partners. It opens access to local manufacturing hubs, regional distribution networks, and regional clinical trial centers.
It gives American management teams something Wall Street rarely offers: immediate local credibility across the Pacific.
Axiom isn't abandoning America. Its primary R&D center stays in San Diego, its clinical trials remain rooted in U.S. medical centers, and its FDA regulatory pathway stays completely intact. The management team intends to pursue a secondary U.S. listing on Nasdaq around 2029.
By that point, Axiom hopes to have Phase 2 data in hand, a healthy cash runway funded by Asian capital, and a higher baseline valuation.
The Two-Step Listing Strategy for US Life Sciences
Axiom's unconventional strategy creates a new blueprint for executive teams at small and mid-sized life sciences firms.
For two decades, the standard startup playbook insisted that primary global capital must come from Boston, New York, or Menlo Park. But as regional capital pools mature in Asia and the Middle East, sticking blindly to that rule can be an expensive mistake.
Comparing the traditional path against the new hybrid model highlights why the math is shifting:
Under the traditional Nasdaq path, early-stage biotechs face high dilution in down-rounds, ruthless short interest, low daily trading volumes, and intense pressure for immediate quarterly results.
Under the hybrid Hong Kong first strategy, companies tap dedicated biotech capital funds under Chapter 18A, leverage lower clinical trial execution costs across Asia, build global partnership networks early, and return to Nasdaq later from a position of financial strength.
If Axiom's 2027 listing succeeds, expect a wave of American life science companies to follow them across the Pacific.
What American Biotech Leaders Should Do Next
If you run a clinical-stage life science company and feel squeezed by U.S. venture markets, sitting on your hands waiting for Wall Street to bounce back isn't a strategy.
Here is how to evaluate whether an international listing makes sense for your pipeline:
- Audit your cap table and clinical ecosystem. If you already rely on Asian supply chains, CROs, or cornerstone investors, a foreign primary listing is far easier to execute.
- Evaluate Chapter 18A clinical readiness. Make sure your lead asset has clean Phase 1 safety data and a clear green light for Phase 2 studies before starting conversations with HKEX sponsors.
- Plan for regulatory double-duty. Running a global strategy means maintaining strict SEC and FDA compliance at home while adhering to HKEX corporate governance requirements abroad.
- Treat the move as a bridge, not an exit. Keep your domestic clinical presence strong so that a secondary Wall Street listing remains viable when market conditions favor mid-cap biotechs again.
The global capital market is shifting. The biotech companies that survive the next decade won't be the ones that stayed loyal to Wall Street—they'll be the ones that went wherever the capital was smartest.
